Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 360

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 360
---
 per share redemption price of $12.17 in connection with the Third Extension Meeting that occurred on 
 April 11, 2025 to amend Denali’s amended and restated memorandum and articles of association.                                                                                                  |

| (2) | The interim redemption scenarios assume the following: |

| Redemption Scenario |     | Number of Denali                 
 Class A Ordinary Shares Redeemed |        |     | Redemption Payments |         |
|:--------------------|:----|:---------------------------------|-------:|:----|:--------------------|--------:|
| 25%                 |     |                                  | 10,935 |     | $                   | 133,079 |
| 50%                 |     |                                  | 21,870 |     | $                   | 266,158 |
| 75%                 |     |                                  | 32,805 |     | $                   | 399,237 |

| (3) | Comprised of 29,117 public shares outstanding as of the date of this proxy statement/prospectus and assumes                                                                                                                                         
 that the holders of 14,622 Public Units have voluntarily separated such units into their component parts prior to the Closing such that the 14,622 public shares underlying such units are available for redemption in connection with the Business 
 Combination.                                                                                                                                                                                                                                        |

| (4) | Excludes 510,000 Denali Private Placement Units held by the Sponsor. In connection with Denali’s IPO, the                                                                                                                                         
 Initial Shareholders agreed they would not exercise any redemption rights with respect to the founder shares. In addition, they agreed that they would not transfer, assign or sell their founder shares until the earliest of (a) one year after 
 the completion of Denali’s initial business combination and (b) subsequent to Denali’s initial business combination, (i) if the closing price of the Denali Class A Ordinary Shares equals or exceeds $12.00 per share (as                        
 adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after                                              
 Denali’s initial business combination, or (ii) the date on which Denali completes a liquidation, merger, share exchange or other similar transaction that results in all of Denali’s public shareholders having the right to exchange             
 their Denali Class A Ordinary Shares for cash, securities or other property.                                                                                                                                                                      |

| (5) | The number of shares of New Sem